Crystal structure of the VRC01-class antibody 12A01, derived from GT1.1 vaccination, in complex with eOD-GT8

N-acetyl-beta-D-glucosamine; 2-acetamido-2-deoxy-beta-D-glucose; 2-acetamido-2-deoxy-D-glucose; 2-acetamido-2-deoxy-glucose; N-ACETYL-D-GLUCOSAMINE

Precise targeting of HIV broadly neutralizing antibody precursors in humans.

QVQLVQSGAEVKQPGASVKVSCKASGYTFSDHFMHWVRQAPGQGLEWMGWINPKSGGPNYAQKFQGRVTMTRDRSISTAY
MELRGLRSDDTAIYYCARPMHDYDDHDWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC

VSVLTQSPGTLSLSPGERATLSCRASQTVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYEAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC

DTITLPCRPAPPPHCSSNITGLILTRQGGYSNANTVIFRPSGGDWRDIARCQIAGTVVSTQLFLNGSLAEEEVVIRSEDW
RDNAKSICVQLATSVEIACTGAGHCAISRAKWANTLKQIASKLREQYGAKTIIFKPSSGGDPEFVNHSFNCGGEFFYCAS
TQLFASTWFASTGTGTKHHHHHH

1.2M sodium dihydrogen phosphate, 0.1M CAPS, 0.8M di-potassium hydrogen phosphate, 25% glycerol, 0.2M lithium sulfate

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

Fab, Germline-targeting vaccination, CD4bs mAb, HIV-1, IMMUNE SYSTEM